Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCB-NK Cells and IL-2 in Acute Myeloid Leukemia
NCT04347616Phase 2Terminated
- Sponsor
- Radboud University Medical Center
- Start
- Dec 2020
- Primary completion
- Jan 2026
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of umbilical cord blood-derived NK cells in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Radboud University Medical Center. Started Dec 2020; status: terminated.
02
Drugs
umbilical cord blood-derived NK cells
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04347616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04347616.